Granules India Ltd Share Price
As on 22 November 2025 at 10:18 IST
Granules India Q1 FY26 Results:
Profit for the period declined 16% to ₹113 crores in Q1 FY26, from ₹135 crores in Q1 FY25. Total income for the quarter increased 4% year-on-year to ₹1,227 crores from ₹1,182 crores.
About Granules India Ltd
Granules India Limited, a pharmaceutical company founded in 1984, has established itself as a significant player in the industry. Headquartered in Hyderabad, Telangana, the company specialises in manufacturing Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs). It is known for producing large-scale quantities of common drugs. They include Paracetamol, Ibuprofen, Metformin, and Guaifenesin. While not the largest in terms of market share or capitalization, Granules India has built a strong reputation. This is based on manufacturing excellence, process innovation, and regulatory expertise. Its reputation has also helped it maintain a competitive edge. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-2.65%
Over 6 Months
8.17%
Over 1 Year
1.09%
Over 3 Years
53.26%
Granules India Ltd Summary
Close ₹550.80
Open ₹556.90
High ₹557.35
Low ₹549
Volume 2,96,113
Net Turnover (in Cr) ₹16.36
52Wk High ₹628
52Wk Low ₹422
52Wk High / Low
422
628
Granules India Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹13,366.19
EPS (TTM) 14.92
Book Value (BV) 146.23
Div. Yield 0.27 %
P/E (TTM) 35.70
Price/Book Value 3.76
Delivery % 43.97 %
Face Value 1
Key Ratios
PE Ratio 36.99
PB Ratio 3.47
EV to Sales 4.14
PEG Ratio -1.38
ROA 7.37
ROE 9.80
Debt-Equity 0.30
Net Profit Margin 10.54
Operating Profit Margin 21
Granules India Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,494.53 | 4,510.77 | 4,525.70 | 3,782.53 | 3,264.42 |
| Total Expenses | 3,865.11 | 3,963.54 | 3,838.52 | 3,224.53 | 2,560.06 |
| Profit Before Tax | 660.17 | 547.23 | 687.17 | 558 | 704.36 |
| Profit After Tax | 501.52 | 405.31 | 516.60 | 412.76 | 549.46 |
| Operating Profit After Depreciation | 732.65 | 653.05 | 743.11 | 581.21 | 730.65 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,429.71 | 2,107.77 | 1,922.26 | 1,585.49 | 1,386.31 |
| Total Non Current Assets | 3,137.08 | 2,615.93 | 2,330.42 | 2,007.92 | 1,716.45 |
| Total Current Assets | 3,115.48 | 2,905.05 | 2,574.15 | 2,504.99 | 1,997 |
| Total Assets | 6,252.56 | 5,520.98 | 4,904.56 | 4,512.90 | 3,713.45 |
| Total Shareholder's Fund | 3,715.58 | 3,225.54 | 2,834.91 | 2,586.54 | 2,173.27 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 866.57 | 439.41 | 738.75 | 332.05 | 432.48 |
| Net Cash Used In Investing Activities | -689.05 | -357.54 | -191.62 | -379.17 | -277.26 |
| Net Cash Used In Financing Activities | -92.51 | 7.66 | -440.29 | 190 | -299.31 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 3,070.84 | 3,760.87 | 3,941.13 | 3,255.95 | 3,148.71 |
| Total Expenses | 2,674.37 | 3,169.58 | 3,277.19 | 2,736.30 | 2,415.84 |
| Profit Before Tax | 427.22 | 591.29 | 663.94 | 519.65 | 732.87 |
| Profit After Tax | 319.34 | 435.92 | 498.79 | 386.51 | 552.78 |
| Operating Profit After Depreciation | 459.25 | 663.29 | 702.61 | 536 | 756.64 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,405.54 | 1,324.08 | 1,329.80 | 1,187.21 | 1,002.43 |
| Total Non Current Assets | 2,864.96 | 2,371.70 | 2,185.30 | 2,041.97 | 1,804.97 |
| Total Current Assets | 2,286.91 | 2,633.92 | 2,317.97 | 2,330.65 | 1,877.87 |
| Total Assets | 5,151.87 | 5,005.63 | 4,503.27 | 4,372.62 | 3,682.83 |
| Total Shareholder's Fund | 3,403.01 | 3,110.95 | 2,699.46 | 2,530.66 | 2,162.62 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 822.71 | 316.93 | 663.68 | 280.29 | 374.66 |
| Net Cash Used In Investing Activities | -553.62 | -301.74 | -96.71 | -317.51 | -232.74 |
| Net Cash Used In Financing Activities | -339.83 | 26.14 | -519.47 | 151.43 | -296.21 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,296.99 | 1,210.11 | 1,197.43 | 1,137.70 | 966.62 |
| Total Expenses | 1,018.76 | 963.39 | 945.07 | 907.40 | 763.30 |
| Profit Before Tax | 175.87 | 144.53 | 197.55 | 152.80 | 128.39 |
| Profit After Tax | 130.61 | 112.64 | 152.03 | 117.60 | 97.23 |
| Operating Profit after Depreciation | 277.08 | 263.07 | 254.28 | 235.98 | 206.58 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 891.61 | 810.21 | 768.03 | 842.20 | 567.99 |
| Total Expenses | 680.20 | 666.57 | 651.11 | 674.33 | 465.39 |
| Profit Before Tax | 161.91 | 91.45 | 126.70 | 118.61 | 56.07 |
| Profit After Tax | 120.61 | 69.49 | 94.05 | 90.11 | 41.39 |
| Operating Profit after Depreciation | 219.30 | 156.79 | 147.41 | 173.48 | 105.38 |
Granules India Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 547.42
S2 544.03
S3 539.07
Pivot 552.38
R1 555.77
R2 560.73
R3 564.12
Moving Average
20 SMA 558.86
50 SMA 550.44
100 SMA 514.39
200 SMA 507.63
Granules India Ltd Corporate Actions
Granules India Ltd
₹1.5/Share
Announcement Date 31 Jul 2025
Record Date 31 Jul 2025
Div Yield 150%
Granules India Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,777.85 | ₹4,26,565.77 |
| Divis Laboratories Ltd | ₹6,463.80 | ₹1,71,593.58 |
| Torrent Pharmaceuticals Ltd | ₹3,717.75 | ₹1,25,819.90 |
| Cipla Ltd | ₹1,528.95 | ₹1,23,504.18 |
| Dr Reddys Laboratories Ltd | ₹1,247.65 | ₹1,04,131.51 |
Granules India Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Old Bridge Focused Fund | 4.08% |
| Aditya Birla SL Value Fund | 2.19% |
| Tata Aggressive Hybrid Fund | 1.50% |
| Aditya Birla SL Small Cap Fund | 1.22% |
| Tata Large Cap Fund | 1.08% |
Granules India Ltd News
Granules India's Hyderabad-based facility gets first U.S. FDA approval
Granules India said that its subsidiary Granules Life Sciences (GLS), located in Hyderabad, has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a pre-approval inspection (PAI).
11 Nov 2025, 11:41 am
Granules Life Sciences receives USFDA approval for its Hyderabad unit
11 Nov 2025, 11:20 am
Granules Pharmaceuticals Inc. concludes USFDA inspection
05 Nov 2025, 10:59 am
Granules India to conduct board meeting
On 13 November 2025
30 Oct 2025, 11:14 am
Granules India gains after USFDA issues EIR for Hyderabad API facility
Granules India advanced 2.04% to Rs 581.15 after the company announced that it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its API Unit-I facility located at Bonthapally, Hyderabad.
29 Oct 2025, 01:40 pm
Granules India Ltd Stock Analysis
- Annual revenue for Granules India Ltd decreased by 18.35% to ₹3,070.84 crore in FY 2025 from ₹3,760.87 crore in FY 2024.
- Annual Net Profit for Granules India Ltd decreased by 26.74% to ₹319.34 crore in FY 2025 from ₹435.92 crore in FY 2024.
- Promoter Shareholding in Granules India Ltd decreased by 0.01% in the most recent quarter, from 38.82% in June 2025 to 38.82% in September 2025.
- Granules India Ltd delivered a 1-year return of 1.09% compared to the Nifty 50, which provided a return of 12.17% as of the last trading session.
- Granules India Ltd share price moved down by 0.91% from its previous close of INR ₹550.80. The latest Granules India Ltd share price is INR ₹545.80.
- Granules India Ltd share price today has been at a low of 543.40 and a high of 551.20. Over the past 52 weeks, the Granules India Ltd share price has seen a low of 422 and a high of 628.
About Granules India Ltd
Granules India Limited, a pharmaceutical company founded in 1984, has established itself as a significant player in the industry. Headquartered in Hyderabad, Telangana, the company specialises in manufacturing Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs).
Dr. Krishna Prasad Chigurupati, the Chairman & Managing Director, owns 31.69% shares of the company. Under his leadership, Granules India has grown to become a globally recognized pharmaceutical manufacturer.
Apart from him, there are a few managerial promoters who have contributed to the success of the company. They are ● Harsha Chigurupati ● Kolli Basava Sankar Rao ● Sucharita Rao Palepu ● Arun Sawhney ● Priyanka Chigurupati The company is known for producing large-scale quantities of common drugs. They include Paracetamol, Ibuprofen, Metformin, and Guaifenesin.
While not the largest in terms of market share or capitalization, Granules India has built a strong reputation. This is based on manufacturing excellence, process innovation, and regulatory expertise. Its reputation has also helped it maintain a competitive edge in the global pharmaceutical landscape.
The company’s registered office is located in Madhapur, Hyderabad, Telangana. Meanwhile, Granules India’s registrars are located in the Financial District. Throughout its history, Granules India has consistently focused on quality and innovation. The company serves the global pharmaceutical market with essential drugs. Its longevity and success in the industry underscore its ability to adapt to changing market conditions.
Granules India places a strong emphasis on quality control and assurance. The company has established robust quality management systems that adhere to international standards. These systems are made to monitor every stage of the manufacturing process, from raw material procurement to the final product. In this way, Granules ensures that each batch of drugs meets the required safety and efficacy standards.
The company’s quality control laboratories are equipped with advanced analytical instruments. These instruments are used to conduct various tests. They include chemical, physical, and microbiological analyses. This comprehensive testing helps identify potential contaminants or deviations from the specified quality parameters. As a result, Granules minimises the risk of contamination and ensures the production of safe and effective drugs.
Compliance with regulatory requirements is a cornerstone of Granules India’s approach to drug safety. The company operates in multiple international markets, each with its own set of regulatory standards. Granules ensures that its manufacturing facilities and processes comply with the regulations of agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).
Granules India has a dedicated regulatory affairs team that stays updated with the latest changes. They ensure that the company’s practices are aligned with these requirements. This team is also responsible for submitting the necessary documentation and managing inspections. As a result, Granules demonstrates its commitment to producing safe and high-quality pharmaceutical products.
Granules India is committed to continuous improvement and innovation in its manufacturing processes. The company invests in research and development (R&D) to enhance the safety and efficacy of its products. This allows Granules to explore new technologies and methodologies. As a result, it can improve drug formulation and enhance product quality.
One of the key areas of focus for Granules is the development of novel drug delivery systems. These systems are designed to improve the bioavailability and therapeutic effectiveness of drugs while minimising side effects. Granules aims to provide patients with safer treatment options by leveraging advanced technologies.
Pharmacovigilance is an integral part of Granules India’s drug safety strategy. The company has established a comprehensive pharmacovigilance system. This is to monitor the safety of its products throughout their lifecycle.
Granules India works with healthcare professionals and patients to gather data on the safety of its products. This information is used to identify potential safety concerns. It is also used to take appropriate actions to mitigate risks. Granules ensure that any safety issues are promptly addressed by maintaining a proactive approach to pharmacovigilance.
Transparency and accountability are fundamental principles that guide Granules India’s operations. The company maintains open communication with regulatory authorities, healthcare professionals, and patients. This helps in building trust and credibility, which are essential for ensuring drug safety.
Granules India also implements robust documentation practices. This is to ensure traceability and accountability in its manufacturing processes. Detailed records are maintained for each batch of drugs. This includes information on raw materials, production parameters, and quality control tests. These records are regularly reviewed and audited to ensure compliance with regulatory requirements.
Granules India’s commitment to drug safety is evident in its comprehensive approach. This includes quality control, regulatory compliance, continuous improvement, pharmacovigilance, training, and transparency. By adhering to these principles, the company ensures that its products are safe, effective, and of the highest quality.
Dr. Krishna Prasad Chigurupati, the Chairman & Managing Director, owns 31.69% shares of the company. Under his leadership, Granules India has grown to become a globally recognized pharmaceutical manufacturer.
Apart from him, there are a few managerial promoters who have contributed to the success of the company. They are ● Harsha Chigurupati ● Kolli Basava Sankar Rao ● Sucharita Rao Palepu ● Arun Sawhney ● Priyanka Chigurupati The company is known for producing large-scale quantities of common drugs. They include Paracetamol, Ibuprofen, Metformin, and Guaifenesin.
While not the largest in terms of market share or capitalization, Granules India has built a strong reputation. This is based on manufacturing excellence, process innovation, and regulatory expertise. Its reputation has also helped it maintain a competitive edge in the global pharmaceutical landscape.
The company’s registered office is located in Madhapur, Hyderabad, Telangana. Meanwhile, Granules India’s registrars are located in the Financial District. Throughout its history, Granules India has consistently focused on quality and innovation. The company serves the global pharmaceutical market with essential drugs. Its longevity and success in the industry underscore its ability to adapt to changing market conditions.
How Granules India Ensures Drug Safety
Granules India is a prominent pharmaceutical company known for its commitment to drug safety and quality. Ensuring the safety of its products is a multifaceted process that involves stringent quality control measures, regulatory compliance, and continuous improvement. Here is a detailed look at how Granules India ensures drug safety.Granules India places a strong emphasis on quality control and assurance. The company has established robust quality management systems that adhere to international standards. These systems are made to monitor every stage of the manufacturing process, from raw material procurement to the final product. In this way, Granules ensures that each batch of drugs meets the required safety and efficacy standards.
The company’s quality control laboratories are equipped with advanced analytical instruments. These instruments are used to conduct various tests. They include chemical, physical, and microbiological analyses. This comprehensive testing helps identify potential contaminants or deviations from the specified quality parameters. As a result, Granules minimises the risk of contamination and ensures the production of safe and effective drugs.
Compliance with regulatory requirements is a cornerstone of Granules India’s approach to drug safety. The company operates in multiple international markets, each with its own set of regulatory standards. Granules ensures that its manufacturing facilities and processes comply with the regulations of agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO).
Granules India has a dedicated regulatory affairs team that stays updated with the latest changes. They ensure that the company’s practices are aligned with these requirements. This team is also responsible for submitting the necessary documentation and managing inspections. As a result, Granules demonstrates its commitment to producing safe and high-quality pharmaceutical products.
Granules India is committed to continuous improvement and innovation in its manufacturing processes. The company invests in research and development (R&D) to enhance the safety and efficacy of its products. This allows Granules to explore new technologies and methodologies. As a result, it can improve drug formulation and enhance product quality.
One of the key areas of focus for Granules is the development of novel drug delivery systems. These systems are designed to improve the bioavailability and therapeutic effectiveness of drugs while minimising side effects. Granules aims to provide patients with safer treatment options by leveraging advanced technologies.
Pharmacovigilance is an integral part of Granules India’s drug safety strategy. The company has established a comprehensive pharmacovigilance system. This is to monitor the safety of its products throughout their lifecycle.
Granules India works with healthcare professionals and patients to gather data on the safety of its products. This information is used to identify potential safety concerns. It is also used to take appropriate actions to mitigate risks. Granules ensure that any safety issues are promptly addressed by maintaining a proactive approach to pharmacovigilance.
Transparency and accountability are fundamental principles that guide Granules India’s operations. The company maintains open communication with regulatory authorities, healthcare professionals, and patients. This helps in building trust and credibility, which are essential for ensuring drug safety.
Granules India also implements robust documentation practices. This is to ensure traceability and accountability in its manufacturing processes. Detailed records are maintained for each batch of drugs. This includes information on raw materials, production parameters, and quality control tests. These records are regularly reviewed and audited to ensure compliance with regulatory requirements.
Granules India’s commitment to drug safety is evident in its comprehensive approach. This includes quality control, regulatory compliance, continuous improvement, pharmacovigilance, training, and transparency. By adhering to these principles, the company ensures that its products are safe, effective, and of the highest quality.
FAQ’s
What is the share price of Granules India Ltd today?
Granules India Ltd share price as on 22 Nov 2025 is ₹ 545.8
What is the Market Cap of Granules India Ltd?
The market cap of Granules India Ltd stock is ₹13,366.19 Cr.
What is the PE Ratio of Granules India Ltd?
The Price to Earnings (P/E) Ratio of Granules India Ltd is 36.99
What is the PB Ratio of Granules India Ltd?
The Price to Book (P/B) Ratio of Granules India Ltd is 3.47
What is the 52 week high of Granules India Ltd Share Price?
The 52 week high of Granules India Ltd share price stands at ₹628
What is the 52 week low of Granules India Ltd Share Price?
The 52 week low of Granules India Ltd share price stands at ₹422
How can I buy shares of Granules India Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Granules India Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
